Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Virtual Congress 2020

Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Dissecting the molecular differences and clinical outcomes of EGFR patients with Exon 19 deletion and Exon 21 L858R mutations

Date

21 Nov 2020

Session

Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Topics

Targeted Therapy

Tumour Site

Presenters

Yi-Long Wu

Authors

Y. Wu

Author affiliations

  • Guangdong Lung Cancer Institute, 510000 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Opening remarks and introduction

Presenter: Ross A. Soo

Session: Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Resources:

Webcast

Case based discussion

Presenter: Ullas Batra

Session: Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Resources:

Webcast

Panel discussion and closing

Presenter: Nellie Cheah Lay Chin

Session: Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.